One of the most popular weight loss drugs on the market may soon be covered by more insurance plans.
Wegovy maker Novo Nordisk said its product could receive expanded approval from the U.S. Food and Drug Administration within six months. CNBC reported. The company has received priority review from the FDA for the use of Wegovy as a treatment to reduce the risk of cardiovascular disease. If approved, the changes could expand insurance coverage for the drug, which was previously approved only for weight loss.
Data in August reported by CNBC showed Wegovy reduced the risk of major cardiovascular events such as heart attacks and strokes by 20% compared to a placebo.
The drug currently has a list price of $1,350 per month in the United States.